Drug recall · February 19, 2020
Memantine Hydrochloride Extended Release Capsules recall
Why: Failed Dissolution Specifications: Low out of specification results observed in dissolution test at six-month long-term stability study.
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
Memantine Hydrochloride Extended Release Capsules, 21 mg, 30-count bottles, Rx Only, Manufactured for: Lupin Pharmaceuticals, Inc. Baltimore, Maryland 21202 United States. Manufactured by: Lupin Limited Pithampur (M.P.)-454 775, INDIA, NDC 68180-248-06
- Lots / codes
Lot #: H900330, exp. date 11/2020.
- Quantity
- 6,294 bottles
- Company
- Lupin Pharmaceuticals Inc., Baltimore, MD
- Distribution
- Nationwide within the United States.
- Initiated
- February 12, 2020 · Voluntary: Firm initiated
- Classified
- February 24, 2020
- Reported
- February 19, 2020
- Ended
- June 3, 2021
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Memantine
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.